In January 2025, Alchemab announced an agreement with Eli Lilly and Company. Under the terms of the agreement, Alchemab will collaborate with Lilly to discover, develop and commercialise up to ...

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients. The importance of biosimilars only continues ...

Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...